1. Home
  2. MODD vs GDTC Comparison

MODD vs GDTC Comparison

Compare MODD & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Modular Medical Inc.

MODD

Modular Medical Inc.

N/A

Current Price

$1.96

Market Cap

11.2M

Sector

Health Care

ML Signal

N/A

Logo CytoMed Therapeutics Limited

GDTC

CytoMed Therapeutics Limited

N/A

Current Price

$0.77

Market Cap

10.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MODD
GDTC
Founded
1998
2018
Country
United States
Singapore
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.2M
10.4M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
MODD
GDTC
Price
$1.96
$0.77
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 114.5K
13.9K
Earning Date
11-13-2026
04-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.12
$0.68
52 Week High
$6.16
$3.68

Technical Indicators

Market Signals
Indicator
MODD
GDTC
Relative Strength Index (RSI) 35.31 45.71
Support Level $1.72 $0.74
Resistance Level $2.49 $1.05
Average True Range (ATR) 0.21 0.09
MACD -0.04 -0.00
Stochastic Oscillator 18.39 36.01

Price Performance

Historical Comparison
MODD
GDTC

About MODD Modular Medical Inc.

Modular Medical Inc is a development stage medical device company which focuses on the design, development, marketing and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.

About GDTC CytoMed Therapeutics Limited

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.

Share on Social Networks: